258 related articles for article (PubMed ID: 31724046)
1. Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens.
Bonomo RA
Clin Infect Dis; 2019 Nov; 69(Suppl 7):S519-S520. PubMed ID: 31724046
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
3.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158270
[TBL] [Abstract][Full Text] [Related]
4. [Discovery of a New Siderophore Cephalosporin, Cefiderocol].
Yamano Y
Yakugaku Zasshi; 2024; 144(6):627-631. PubMed ID: 38825471
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
Golden AR; Adam HJ; Baxter M; Walkty A; Lagacé-Wiens P; Karlowsky JA; Zhanel GG
Diagn Microbiol Infect Dis; 2020 May; 97(1):115012. PubMed ID: 32081522
[TBL] [Abstract][Full Text] [Related]
6. Cefiderocol: A new Antimicrobial for Complicated Urinary Tract Infection (CUTI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE).
Chatterjee S; Chakraborty DS; Choudhury S; Lahiry S
Curr Drug Res Rev; 2022; 14(1):20-23. PubMed ID: 34872487
[TBL] [Abstract][Full Text] [Related]
7. ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and
Jacobs MR; Abdelhamed AM; Good CE; Rhoads DD; Hujer KM; Hujer AM; Domitrovic TN; Rudin SD; Richter SS; van Duin D; Kreiswirth BN; Greco C; Fouts DE; Bonomo RA
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323050
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin.
Sato T; Yamawaki K
Clin Infect Dis; 2019 Nov; 69(Suppl 7):S538-S543. PubMed ID: 31724047
[TBL] [Abstract][Full Text] [Related]
9. Cefiderocol: A Siderophore Cephalosporin.
El-Lababidi RM; Rizk JG
Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria.
Yamano Y
Clin Infect Dis; 2019 Nov; 69(Suppl 7):S544-S551. PubMed ID: 31724049
[TBL] [Abstract][Full Text] [Related]
11. Cefiderocol: a novel siderophore cephalosporin.
Choi JJ; McCarthy MW
Expert Opin Investig Drugs; 2018 Feb; 27(2):193-197. PubMed ID: 29318906
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-Resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety.
Lee YR; Yeo S
Clin Drug Investig; 2020 Oct; 40(10):901-913. PubMed ID: 32700154
[TBL] [Abstract][Full Text] [Related]
13. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015.
Karlowsky JA; Hackel MA; Tsuji M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Apr; 53(4):456-466. PubMed ID: 30471402
[TBL] [Abstract][Full Text] [Related]
15. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
[TBL] [Abstract][Full Text] [Related]
16.
Hackel MA; Tsuji M; Yamano Y; Echols R; Karlowsky JA; Sahm DF
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630181
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
Jorda A; Zeitlinger M
Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
[No Abstract] [Full Text] [Related]
18. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
Syed YY
Drugs; 2021 Sep; 81(13):1559-1571. PubMed ID: 34427896
[TBL] [Abstract][Full Text] [Related]
19. Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
Aoki T; Yoshizawa H; Yamawaki K; Yokoo K; Sato J; Hisakawa S; Hasegawa Y; Kusano H; Sano M; Sugimoto H; Nishitani Y; Sato T; Tsuji M; Nakamura R; Nishikawa T; Yamano Y
Eur J Med Chem; 2018 Jul; 155():847-868. PubMed ID: 29960205
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
